Review



cancer pathways kit  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc cancer pathways kit
    Cancer Pathways Kit, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/pSG5+Large+T+(Plasmid+%239053)/pmc08496177-294-14-17
    Average 93 stars, based on 24 article reviews
    cancer pathways kit - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Polymerase Chain Reaction:

    Article Title: Charting oncogenicity of genes and variants across lineages via multiplexed screens in teratomas
    Article Snippet: .. To create the driver ORF library, individual drivers were PCR amplified out of the Cancer Pathways kit (Addgene #1000000072) , individual plasmids (Addgene #9053, #85140, #82262, #82297, #82175, #61852, #39872, #23776, #23688, #10745, #23231) ( ; ; ; ; ; ), a human cDNA pool (Promega Corporation), or obtained as synthesized double-stranded DNA fragments (gBlocks, IDT Inc) with flanking sequences compatible with the BamHI restriction sites. .. The barcoded lentiviral backbone was digested with BamHI HF (New England Biolabs) at 37°C for 3 hours in a reaction consisting of: lentiviral backbone, 4 μg, CutSmart buffer, 5 μl, BamHI, 0.625 μl, H 2 0 up to 50 μl.

    Article Title: Charting oncogenicity of genes and variants across lineages via multiplexed screens in teratomas
    Article Snippet: .. To create the driver ORF library, individual drivers were PCR amplified out of the Cancer Pathways kit (Addgene #1000000072) , individual plasmids (Addgene #9053, #85140, #82262, #82297, #82175, #61852, #39872, #23776, #23688, #10745, #23231) – , a human cDNA pool (Promega Corporation), or obtained as synthesized double-stranded DNA fragments (gBlocks, IDT Inc) with flanking sequences compatible with the BamHI restriction sites. .. The barcoded lentiviral backbone was digested with BamHI HF (New England Biolabs) at 37 0C for 3 hours in a reaction consisting of: lentiviral backbone, 4 μg, CutSmart buffer, 5 μl, BamHI, 0.625 μl, H 2 0 up to 50 μl.

    Amplification:

    Article Title: Charting oncogenicity of genes and variants across lineages via multiplexed screens in teratomas
    Article Snippet: .. To create the driver ORF library, individual drivers were PCR amplified out of the Cancer Pathways kit (Addgene #1000000072) , individual plasmids (Addgene #9053, #85140, #82262, #82297, #82175, #61852, #39872, #23776, #23688, #10745, #23231) ( ; ; ; ; ; ), a human cDNA pool (Promega Corporation), or obtained as synthesized double-stranded DNA fragments (gBlocks, IDT Inc) with flanking sequences compatible with the BamHI restriction sites. .. The barcoded lentiviral backbone was digested with BamHI HF (New England Biolabs) at 37°C for 3 hours in a reaction consisting of: lentiviral backbone, 4 μg, CutSmart buffer, 5 μl, BamHI, 0.625 μl, H 2 0 up to 50 μl.

    Article Title: Charting oncogenicity of genes and variants across lineages via multiplexed screens in teratomas
    Article Snippet: .. To create the driver ORF library, individual drivers were PCR amplified out of the Cancer Pathways kit (Addgene #1000000072) , individual plasmids (Addgene #9053, #85140, #82262, #82297, #82175, #61852, #39872, #23776, #23688, #10745, #23231) – , a human cDNA pool (Promega Corporation), or obtained as synthesized double-stranded DNA fragments (gBlocks, IDT Inc) with flanking sequences compatible with the BamHI restriction sites. .. The barcoded lentiviral backbone was digested with BamHI HF (New England Biolabs) at 37 0C for 3 hours in a reaction consisting of: lentiviral backbone, 4 μg, CutSmart buffer, 5 μl, BamHI, 0.625 μl, H 2 0 up to 50 μl.

    Synthesized:

    Article Title: Charting oncogenicity of genes and variants across lineages via multiplexed screens in teratomas
    Article Snippet: .. To create the driver ORF library, individual drivers were PCR amplified out of the Cancer Pathways kit (Addgene #1000000072) , individual plasmids (Addgene #9053, #85140, #82262, #82297, #82175, #61852, #39872, #23776, #23688, #10745, #23231) ( ; ; ; ; ; ), a human cDNA pool (Promega Corporation), or obtained as synthesized double-stranded DNA fragments (gBlocks, IDT Inc) with flanking sequences compatible with the BamHI restriction sites. .. The barcoded lentiviral backbone was digested with BamHI HF (New England Biolabs) at 37°C for 3 hours in a reaction consisting of: lentiviral backbone, 4 μg, CutSmart buffer, 5 μl, BamHI, 0.625 μl, H 2 0 up to 50 μl.

    Article Title: Charting oncogenicity of genes and variants across lineages via multiplexed screens in teratomas
    Article Snippet: .. To create the driver ORF library, individual drivers were PCR amplified out of the Cancer Pathways kit (Addgene #1000000072) , individual plasmids (Addgene #9053, #85140, #82262, #82297, #82175, #61852, #39872, #23776, #23688, #10745, #23231) – , a human cDNA pool (Promega Corporation), or obtained as synthesized double-stranded DNA fragments (gBlocks, IDT Inc) with flanking sequences compatible with the BamHI restriction sites. .. The barcoded lentiviral backbone was digested with BamHI HF (New England Biolabs) at 37 0C for 3 hours in a reaction consisting of: lentiviral backbone, 4 μg, CutSmart buffer, 5 μl, BamHI, 0.625 μl, H 2 0 up to 50 μl.



    Similar Products

    90
    Qiagen cignal finder cancer 10-pathway reporter array kit
    Cignal Finder Cancer 10 Pathway Reporter Array Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/cignal+45+pathway+reporter+array/pm37987774-100-14-22
    Average 90 stars, based on 1 article reviews
    cignal finder cancer 10-pathway reporter array kit - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Millipore flowcellect pi3k/mapk dual pathway activation and cancer marker detection kit
    Flowcellect Pi3k/Mapk Dual Pathway Activation And Cancer Marker Detection Kit, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/ly294002/pm36302719-189-12-5
    Average 90 stars, based on 1 article reviews
    flowcellect pi3k/mapk dual pathway activation and cancer marker detection kit - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Qiagen cignal finder cancer pathway array kit
    Cignal Finder Cancer Pathway Array Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/cignal+45+pathway+reporter+array/pm34515990-45-14-20
    Average 90 stars, based on 1 article reviews
    cignal finder cancer pathway array kit - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    93
    Addgene inc cancer pathways kit
    Cancer Pathways Kit, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/pSG5+Large+T+(Plasmid+%239053)/pmc08496177-294-14-17
    Average 93 stars, based on 1 article reviews
    cancer pathways kit - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Qiagen cancer pathway kits
    Cancer Pathway Kits, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/cancer+pathway+kit/pmc07519550__12860_2020_313_MOESM4_ESM-3-11-17
    Average 90 stars, based on 1 article reviews
    cancer pathway kits - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Qiagen miscript mirna pcr array human cancer pathway kit
    The m6A Methyltransferase METTL3, the m6A Demethylase FTO, and α-Ketoglutarate Regulate the N6-Adenosine Methylation of miR-200b-3p (A) Each bar represents the relative expression level of miR-200b-3p (miR-200b-3p exp ) in 32 samples of GBM. After <t>miRNA</t> extraction from tumors, <t>qRT-PCR</t> was performed to evaluate the relative expression level of miRNA-200b-3p by using non-tumor brain samples as a reference and SNORD6.1 as a housekeeping miRNA. (B) Correlation between the relative expression level of miR-200b-3p and the percentage of N6-adenosine methylation in miR-200b-3p (miR200b-3p %m6A ). This percentage was calculated via the realization of RNA immunoprecipitation (IP) performed with an anti-m6A antibody followed by qPCR analysis (miRIP m6A -qPCR) (as previously described by Berulava et al. ). Each square represents a GBM patient. (C) Absence of correlation between the relative expression level of FTO and the percentage of N6-adenosine methylation in miR-200b-3b. A human FTO ELISA kit (Tebu-Bio, France) was used to estimate the FTO expression. Each square represents a GBM patient. (D) Absence of correlation between the relative presence of α-ketoglutarate (αKG) and the percentage of N6-adenosine methylation in miR-200b-3p. An αKG assay kit (Abcam, France) was used to estimate the relative presence of αKG. Each square represents a GBM patient. (E) High percentage of N6-adenosine methylation in miR-200b-3p is observed in GBM harboring a low level of FTO and αKG. Each square represents a GBM patient. Red squares represent the average ± standard deviation of the two considered subgroups. (F) Impact of the downregulation of FTO on the adenosine methylation percentage of miR-200b-3p% m6A calculated through the realization of miRIP m6A -qPCR as previously described. (G) Impact of the αKG treatment on the adenosine methylation percentage of miR-200b-3p (miRNA-200b-3p %m6A ). (H) Impact of the meclofenamic acid (MA) treatment on miRNA-200b-3p %m6A in U87 cells. After MA treatment (15 μM/24 h, Santa Cruz, France), the miRNA-200b-3p %m6A was calculated through the realization of miRIP m6A -qPCR as previously described. (I) Correlation between the relative expression level of METTL3 and the percentage of N6-adenosine methylation in miR-200b-3p. Each square represents a GBM patient. (J) Dot blot illustrating the presence of adenosine methylation in mimetic miR-200b-3p in the presence of METTL3 IP product. Adenosine detection is used as a control. S1/S2/S3 are three independent experiments. Ctrl, synthetic miR-200b-3p adenosine unmethylated; IP-IgG, product of IP performed with anti-IgG (the absence of an adenosine signal indicates that miRNA was not unspecifically immunoprecipitated); IP-METTL3, product of IP performed with anti-IgG. Products of IP were obtained in non-denaturing conditions in order to conserve enzymatic activity according to the manufacturer’s indications. (K) METTL3 knockdown (by siRNA approach) decreases the percentage of adenosine methylation of miR-200b-3p. (L) αFM score reflects the METTL3, FTO, and αKG expression levels in the 32 GBM samples. Each circle represents a GBM patient. The αFM score is higher when the percentage of adenosine methylation of miR-200b-3p is higher.
    Miscript Mirna Pcr Array Human Cancer Pathway Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/miscript+mirna+pcr+array+human+cancer+pathway+finder/pmc07490450-195-59-67
    Average 90 stars, based on 1 article reviews
    miscript mirna pcr array human cancer pathway kit - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Qiagen cignal findertm cancer 10-pathway reporter arrays kit
    The m6A Methyltransferase METTL3, the m6A Demethylase FTO, and α-Ketoglutarate Regulate the N6-Adenosine Methylation of miR-200b-3p (A) Each bar represents the relative expression level of miR-200b-3p (miR-200b-3p exp ) in 32 samples of GBM. After <t>miRNA</t> extraction from tumors, <t>qRT-PCR</t> was performed to evaluate the relative expression level of miRNA-200b-3p by using non-tumor brain samples as a reference and SNORD6.1 as a housekeeping miRNA. (B) Correlation between the relative expression level of miR-200b-3p and the percentage of N6-adenosine methylation in miR-200b-3p (miR200b-3p %m6A ). This percentage was calculated via the realization of RNA immunoprecipitation (IP) performed with an anti-m6A antibody followed by qPCR analysis (miRIP m6A -qPCR) (as previously described by Berulava et al. ). Each square represents a GBM patient. (C) Absence of correlation between the relative expression level of FTO and the percentage of N6-adenosine methylation in miR-200b-3b. A human FTO ELISA kit (Tebu-Bio, France) was used to estimate the FTO expression. Each square represents a GBM patient. (D) Absence of correlation between the relative presence of α-ketoglutarate (αKG) and the percentage of N6-adenosine methylation in miR-200b-3p. An αKG assay kit (Abcam, France) was used to estimate the relative presence of αKG. Each square represents a GBM patient. (E) High percentage of N6-adenosine methylation in miR-200b-3p is observed in GBM harboring a low level of FTO and αKG. Each square represents a GBM patient. Red squares represent the average ± standard deviation of the two considered subgroups. (F) Impact of the downregulation of FTO on the adenosine methylation percentage of miR-200b-3p% m6A calculated through the realization of miRIP m6A -qPCR as previously described. (G) Impact of the αKG treatment on the adenosine methylation percentage of miR-200b-3p (miRNA-200b-3p %m6A ). (H) Impact of the meclofenamic acid (MA) treatment on miRNA-200b-3p %m6A in U87 cells. After MA treatment (15 μM/24 h, Santa Cruz, France), the miRNA-200b-3p %m6A was calculated through the realization of miRIP m6A -qPCR as previously described. (I) Correlation between the relative expression level of METTL3 and the percentage of N6-adenosine methylation in miR-200b-3p. Each square represents a GBM patient. (J) Dot blot illustrating the presence of adenosine methylation in mimetic miR-200b-3p in the presence of METTL3 IP product. Adenosine detection is used as a control. S1/S2/S3 are three independent experiments. Ctrl, synthetic miR-200b-3p adenosine unmethylated; IP-IgG, product of IP performed with anti-IgG (the absence of an adenosine signal indicates that miRNA was not unspecifically immunoprecipitated); IP-METTL3, product of IP performed with anti-IgG. Products of IP were obtained in non-denaturing conditions in order to conserve enzymatic activity according to the manufacturer’s indications. (K) METTL3 knockdown (by siRNA approach) decreases the percentage of adenosine methylation of miR-200b-3p. (L) αFM score reflects the METTL3, FTO, and αKG expression levels in the 32 GBM samples. Each circle represents a GBM patient. The αFM score is higher when the percentage of adenosine methylation of miR-200b-3p is higher.
    Cignal Findertm Cancer 10 Pathway Reporter Arrays Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/cignal+findertm+cancer+10+pathway+reporter+arrays+kit/pm29371679-238-13-20
    Average 90 stars, based on 1 article reviews
    cignal findertm cancer 10-pathway reporter arrays kit - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Qiagen cancer 10-pathway reporter luciferase kit
    The m6A Methyltransferase METTL3, the m6A Demethylase FTO, and α-Ketoglutarate Regulate the N6-Adenosine Methylation of miR-200b-3p (A) Each bar represents the relative expression level of miR-200b-3p (miR-200b-3p exp ) in 32 samples of GBM. After <t>miRNA</t> extraction from tumors, <t>qRT-PCR</t> was performed to evaluate the relative expression level of miRNA-200b-3p by using non-tumor brain samples as a reference and SNORD6.1 as a housekeeping miRNA. (B) Correlation between the relative expression level of miR-200b-3p and the percentage of N6-adenosine methylation in miR-200b-3p (miR200b-3p %m6A ). This percentage was calculated via the realization of RNA immunoprecipitation (IP) performed with an anti-m6A antibody followed by qPCR analysis (miRIP m6A -qPCR) (as previously described by Berulava et al. ). Each square represents a GBM patient. (C) Absence of correlation between the relative expression level of FTO and the percentage of N6-adenosine methylation in miR-200b-3b. A human FTO ELISA kit (Tebu-Bio, France) was used to estimate the FTO expression. Each square represents a GBM patient. (D) Absence of correlation between the relative presence of α-ketoglutarate (αKG) and the percentage of N6-adenosine methylation in miR-200b-3p. An αKG assay kit (Abcam, France) was used to estimate the relative presence of αKG. Each square represents a GBM patient. (E) High percentage of N6-adenosine methylation in miR-200b-3p is observed in GBM harboring a low level of FTO and αKG. Each square represents a GBM patient. Red squares represent the average ± standard deviation of the two considered subgroups. (F) Impact of the downregulation of FTO on the adenosine methylation percentage of miR-200b-3p% m6A calculated through the realization of miRIP m6A -qPCR as previously described. (G) Impact of the αKG treatment on the adenosine methylation percentage of miR-200b-3p (miRNA-200b-3p %m6A ). (H) Impact of the meclofenamic acid (MA) treatment on miRNA-200b-3p %m6A in U87 cells. After MA treatment (15 μM/24 h, Santa Cruz, France), the miRNA-200b-3p %m6A was calculated through the realization of miRIP m6A -qPCR as previously described. (I) Correlation between the relative expression level of METTL3 and the percentage of N6-adenosine methylation in miR-200b-3p. Each square represents a GBM patient. (J) Dot blot illustrating the presence of adenosine methylation in mimetic miR-200b-3p in the presence of METTL3 IP product. Adenosine detection is used as a control. S1/S2/S3 are three independent experiments. Ctrl, synthetic miR-200b-3p adenosine unmethylated; IP-IgG, product of IP performed with anti-IgG (the absence of an adenosine signal indicates that miRNA was not unspecifically immunoprecipitated); IP-METTL3, product of IP performed with anti-IgG. Products of IP were obtained in non-denaturing conditions in order to conserve enzymatic activity according to the manufacturer’s indications. (K) METTL3 knockdown (by siRNA approach) decreases the percentage of adenosine methylation of miR-200b-3p. (L) αFM score reflects the METTL3, FTO, and αKG expression levels in the 32 GBM samples. Each circle represents a GBM patient. The αFM score is higher when the percentage of adenosine methylation of miR-200b-3p is higher.
    Cancer 10 Pathway Reporter Luciferase Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cancer+pathways+kit/cignal+45+pathway+reporter+array/pm29730415-93-1-6
    Average 90 stars, based on 1 article reviews
    cancer 10-pathway reporter luciferase kit - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    The m6A Methyltransferase METTL3, the m6A Demethylase FTO, and α-Ketoglutarate Regulate the N6-Adenosine Methylation of miR-200b-3p (A) Each bar represents the relative expression level of miR-200b-3p (miR-200b-3p exp ) in 32 samples of GBM. After miRNA extraction from tumors, qRT-PCR was performed to evaluate the relative expression level of miRNA-200b-3p by using non-tumor brain samples as a reference and SNORD6.1 as a housekeeping miRNA. (B) Correlation between the relative expression level of miR-200b-3p and the percentage of N6-adenosine methylation in miR-200b-3p (miR200b-3p %m6A ). This percentage was calculated via the realization of RNA immunoprecipitation (IP) performed with an anti-m6A antibody followed by qPCR analysis (miRIP m6A -qPCR) (as previously described by Berulava et al. ). Each square represents a GBM patient. (C) Absence of correlation between the relative expression level of FTO and the percentage of N6-adenosine methylation in miR-200b-3b. A human FTO ELISA kit (Tebu-Bio, France) was used to estimate the FTO expression. Each square represents a GBM patient. (D) Absence of correlation between the relative presence of α-ketoglutarate (αKG) and the percentage of N6-adenosine methylation in miR-200b-3p. An αKG assay kit (Abcam, France) was used to estimate the relative presence of αKG. Each square represents a GBM patient. (E) High percentage of N6-adenosine methylation in miR-200b-3p is observed in GBM harboring a low level of FTO and αKG. Each square represents a GBM patient. Red squares represent the average ± standard deviation of the two considered subgroups. (F) Impact of the downregulation of FTO on the adenosine methylation percentage of miR-200b-3p% m6A calculated through the realization of miRIP m6A -qPCR as previously described. (G) Impact of the αKG treatment on the adenosine methylation percentage of miR-200b-3p (miRNA-200b-3p %m6A ). (H) Impact of the meclofenamic acid (MA) treatment on miRNA-200b-3p %m6A in U87 cells. After MA treatment (15 μM/24 h, Santa Cruz, France), the miRNA-200b-3p %m6A was calculated through the realization of miRIP m6A -qPCR as previously described. (I) Correlation between the relative expression level of METTL3 and the percentage of N6-adenosine methylation in miR-200b-3p. Each square represents a GBM patient. (J) Dot blot illustrating the presence of adenosine methylation in mimetic miR-200b-3p in the presence of METTL3 IP product. Adenosine detection is used as a control. S1/S2/S3 are three independent experiments. Ctrl, synthetic miR-200b-3p adenosine unmethylated; IP-IgG, product of IP performed with anti-IgG (the absence of an adenosine signal indicates that miRNA was not unspecifically immunoprecipitated); IP-METTL3, product of IP performed with anti-IgG. Products of IP were obtained in non-denaturing conditions in order to conserve enzymatic activity according to the manufacturer’s indications. (K) METTL3 knockdown (by siRNA approach) decreases the percentage of adenosine methylation of miR-200b-3p. (L) αFM score reflects the METTL3, FTO, and αKG expression levels in the 32 GBM samples. Each circle represents a GBM patient. The αFM score is higher when the percentage of adenosine methylation of miR-200b-3p is higher.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool

    doi: 10.1016/j.omtn.2020.08.010

    Figure Lengend Snippet: The m6A Methyltransferase METTL3, the m6A Demethylase FTO, and α-Ketoglutarate Regulate the N6-Adenosine Methylation of miR-200b-3p (A) Each bar represents the relative expression level of miR-200b-3p (miR-200b-3p exp ) in 32 samples of GBM. After miRNA extraction from tumors, qRT-PCR was performed to evaluate the relative expression level of miRNA-200b-3p by using non-tumor brain samples as a reference and SNORD6.1 as a housekeeping miRNA. (B) Correlation between the relative expression level of miR-200b-3p and the percentage of N6-adenosine methylation in miR-200b-3p (miR200b-3p %m6A ). This percentage was calculated via the realization of RNA immunoprecipitation (IP) performed with an anti-m6A antibody followed by qPCR analysis (miRIP m6A -qPCR) (as previously described by Berulava et al. ). Each square represents a GBM patient. (C) Absence of correlation between the relative expression level of FTO and the percentage of N6-adenosine methylation in miR-200b-3b. A human FTO ELISA kit (Tebu-Bio, France) was used to estimate the FTO expression. Each square represents a GBM patient. (D) Absence of correlation between the relative presence of α-ketoglutarate (αKG) and the percentage of N6-adenosine methylation in miR-200b-3p. An αKG assay kit (Abcam, France) was used to estimate the relative presence of αKG. Each square represents a GBM patient. (E) High percentage of N6-adenosine methylation in miR-200b-3p is observed in GBM harboring a low level of FTO and αKG. Each square represents a GBM patient. Red squares represent the average ± standard deviation of the two considered subgroups. (F) Impact of the downregulation of FTO on the adenosine methylation percentage of miR-200b-3p% m6A calculated through the realization of miRIP m6A -qPCR as previously described. (G) Impact of the αKG treatment on the adenosine methylation percentage of miR-200b-3p (miRNA-200b-3p %m6A ). (H) Impact of the meclofenamic acid (MA) treatment on miRNA-200b-3p %m6A in U87 cells. After MA treatment (15 μM/24 h, Santa Cruz, France), the miRNA-200b-3p %m6A was calculated through the realization of miRIP m6A -qPCR as previously described. (I) Correlation between the relative expression level of METTL3 and the percentage of N6-adenosine methylation in miR-200b-3p. Each square represents a GBM patient. (J) Dot blot illustrating the presence of adenosine methylation in mimetic miR-200b-3p in the presence of METTL3 IP product. Adenosine detection is used as a control. S1/S2/S3 are three independent experiments. Ctrl, synthetic miR-200b-3p adenosine unmethylated; IP-IgG, product of IP performed with anti-IgG (the absence of an adenosine signal indicates that miRNA was not unspecifically immunoprecipitated); IP-METTL3, product of IP performed with anti-IgG. Products of IP were obtained in non-denaturing conditions in order to conserve enzymatic activity according to the manufacturer’s indications. (K) METTL3 knockdown (by siRNA approach) decreases the percentage of adenosine methylation of miR-200b-3p. (L) αFM score reflects the METTL3, FTO, and αKG expression levels in the 32 GBM samples. Each circle represents a GBM patient. The αFM score is higher when the percentage of adenosine methylation of miR-200b-3p is higher.

    Article Snippet: The reaction was carried out using a Dynabeads protein G IP kit with some modifications (Thermo Fisher Scientific, France) such as described by Berulava et al. As a control, IP was performed using IgG (Abcam, France) instead of anti-m6A antibody. miRNAs obtained from m6A IP were reverse transcribed using miRScript II RT kit (QIAGEN, France) and analyzed using the miScript miRNA PCR array human cancer pathway kit (QIAGEN, France) according to the manufacturers’ instructions.

    Techniques: Methylation, Expressing, Quantitative RT-PCR, Immunoprecipitation, Enzyme-linked Immunosorbent Assay, Standard Deviation, Dot Blot, Activity Assay